Skip to main content
. Author manuscript; available in PMC: 2020 Aug 15.
Published in final edited form as: Clin Cancer Res. 2019 Nov 6;26(4):892–901. doi: 10.1158/1078-0432.CCR-19-0556

Figure 4. Genomic subtyping was associated with survival of LCNEC patients treated with different chemotherapy regimens.

Figure 4.

A-D: the genomic subtyping was based on the presence (SCLC-like) or absence (NSCLC-Like) of co-alterations in TP53 and RB1 (Criterion 1). E-H: the genomic subtyping was based on the presence (SCLC-like) or absence (NSCLC-Like) of any of the following alterations: RB1 mutation or loss, PTEN loss/mutation, FGFR1/FGFR4 mutation/amplification, TP53 loss (Criterion 2). SCLC-PE: etoposide-platinum doublets. NSCLC-GEM/TAX: gemcitabine or taxane-platinum doublets. NSCLC-PEM: pemetrexed-platinum doublets. 54 patients with first line chemotherapy were included in survival analysis.